Table 3.

Complications and treatment of study participants.

Parameter	Influenza A(H1N1) pdm09 A N = 23	p-value A vs. B	Moderate COVID-19 B N = 10	p-value B vs. C	Severe COVID-19 C N = 24	p-value A vs. C
Complications Acute myocardial infarction Deep vein thrombosis Acute kidney injury Secondary infection	3 (13.04) 1 (4.34) 10 (43.47) 14 (60.86)	0.5363 >0.9999 0.0148 0.0014	0 (0) 0 (0) 0 (0) 0 (0)	1 1 0.0815 0.0169	0 (0) 0 (0) 6 (25) 10 (41.66)	0.1092 0.4894 0.1814 0.1880
Medical treatment Oseltamivir Antibiotic therapy No. of antibiotics per patient, median (range) Chloroquine/hydroxychloroquine Azithromycin Corticosteroids	23 (100) 23 (100) 3.5 (2 – 10) 0 (0) 0 (0) 4 (17.39)	0.0012 1 0.0077 <0.0001 <0.0001 0.2890	6 (60) 10 (100) 2 (2 – 3) 10 (100) 10 (100) 0 (0)	0.9283 1 0.0252 <0.0001 0.0049 0.2908	14 (58.33) 24 (100) 4 (3 – 5) 23 (95.83) 13 (54.16) 5 (20.83)	0.0005 1 >0.9999 <0.0001 <0.0001 0.7643
Respiratory support Nasal cannula MV Prone position ECMO	0 (0) 23 (100) 14 (60.86) 2 (8.69)	<0.0001 <0.0001 0.0014 0.3360	10 (100) 0 (0) 0 (0) 0 (0)	<0.0001 <0.0001 0.0135 1	0 (0) 24 (100) 11 (45.83) 0 (0)	1 1 0.3017 0.2340
Renal replacement therapy	6 (26.08)	0.1445	0 (0)	0.2908	5 (20.83)	0.4252
Mortality	5 (21.73)	0.2911	0 (0)	0.0135	15 (62.5)	0.0077

Data are displayed as n (%) or median (IQR). N is the total number of patients with available data. ECMO, extracorporeal membrane oxygenation; IQR, interquartile range; MV, mechanical ventilation; SD, standard deviation. Differences in continuous variables were estimated using the Kruskal Wallis with post hoc Dunn´s test. Differences in categorical variables were calculated using the Fisher’s exact or the Chi-square test as appropriate.